- Record: found
- Abstract: found
- Article: not found
Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer.
Eric J Small
1 ,
Paul F Schellhammer ,
Celestia S Higano ,
Charles H Redfern ,
John J Nemunaitis ,
Frank H Valone ,
Suleman S Verjee ,
Lori A Jones ,
Robert M Hershberg
Jul 01 2006
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Sipuleucel-T (APC8015) is an investigational immunotherapy product designed to stimulate T-cell immunity against prostatic acid phosphatase. A phase III study was undertaken to evaluate the safety and efficacy of sipuleucel-T in a placebo-controlled study.